An Arcus Insider Sold 68,569 Shares but Kept 1.2 Million After a 200% Run

Juan C. Jaen, president of Arcus Biosciences, sold 68,569 shares for $2.0 million through a trust under a Rule 10b5-1 trading plan, while maintaining ~1.2 million shares. The sale appears motivated by tax and liquidity management following a 200% stock surge. Arcus has refocused on casdatifan, its HIF-2α kidney cancer drug, after discontinuing a lung cancer program, with pivotal Phase 3 readouts expected by year-end.